How did Cocrystal Pharma's Q4 2024 expenses impact its operating profit?

Cocrystal Pharma's Q4 2024 expenses had a significant negative impact on its operating profit, with the company reporting an operating income of -$3.18 million for the quarter. This indicates that the company's expenses far exceeded its revenues during this period, resulting in a substantial loss. |code|Ticker|Name|Date|Operating Income|Total Expenses|market_code| |---|---|---|---|---|---|---| |COCP|COCP.O|Cocrystal Pharma|2024 Q1|-3938000||186| |COCP|COCP.O|Cocrystal Pharma|2024 Q2|-5297000||186| |COCP|COCP.O|Cocrystal Pharma|2024 Q3|-4931000||186| |COCP|COCP.O|Cocrystal Pharma|2024 Q4|-3175000||186|